IF 0.9 4区医学

Herz Pub Date : 2026-02-01 Epub Date: 2025-06-26 DOI: 10.1007/s00059-025-05325-x

Moritz Blum, Mark Weber-Krüger, Hashim Abdul-Khaliq, Bernd Alt-Epping, Marc Dittrich, Tanja Henking, Gerald Neitzke, Harald Rittger, Henrikje Stanze, Dorit Knappe, Klaus K Witte, Jochen Dutzmann, Franz Goss

{"title":"[Palliative care and change in treatment goals for heart failure in the outpatient sector : A survey among office-based physicians in Germany on the current state of healthcare provision].","authors":"Moritz Blum, Mark Weber-Krüger, Hashim Abdul-Khaliq, Bernd Alt-Epping, Marc Dittrich, Tanja Henking, Gerald Neitzke, Harald Rittger, Henrikje Stanze, Dorit Knappe, Klaus K Witte, Jochen Dutzmann, Franz Goss","doi":"10.1007/s00059-025-05325-x","DOIUrl":"10.1007/s00059-025-05325-x","url":null,"abstract":"Background: Palliative care is a crucial part of the holistic management of advanced heart failure; however, it remains unclear how palliative care is currently provided in the outpatient sector in Germany.Methods: We conducted a survey among office-based cardiologists and general practitioners (GPs) in Germany on the current provision of palliative care for people with advanced heart failure. The survey was developed by a multiprofessional project group of the German Cardiac Society (DGK e. V.) and administered online by the National Association of Office-Based Cardiologists (BNK e.V.).Results: A total of 235 individuals participated in the study. The majority of respondents reported frequently or always discussing goals of care with patients with advanced heart failure. The GPs reported significantly more often than cardiologists that they always or frequently address primary palliative care needs. None of the surveyed office-based cardiologists but 35.1% of GPs stated that they frequently or always prescribe specialized outpatient palliative care (SAPV) for patients with advanced heart failure. Over 90% of the cardiologists reported that they rarely or never continue to care for patients when they cannot come to the practice themselves.Conclusion: Only few office-based physicians in Germany regularly refer patients with advanced heart failure to specialized palliative care services. Primary palliative care and the involvement of SAPV are significantly more often managed by GPs than by office-based cardiologists.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"45-55"},"PeriodicalIF":0.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12855335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognosticating short-term outcomes in patients with STEMI-ACS and intra-procedural slow-flow/no-reflow phenomenon. STEMI-ACS患者术中慢流/无血流现象的短期预后

IF 0.9 4区医学

Herz Pub Date : 2026-02-01 Epub Date: 2025-08-14 DOI: 10.1007/s00059-025-05326-w

Rajesh Kumar, Abdul Hakeem Shaikh, Ayaz Mir, Uroosa Safdar, Ishrat Fatima, Mahesh Kumar Batra, Musa Karim

{"title":"Prognosticating short-term outcomes in patients with STEMI-ACS and intra-procedural slow-flow/no-reflow phenomenon.","authors":"Rajesh Kumar, Abdul Hakeem Shaikh, Ayaz Mir, Uroosa Safdar, Ishrat Fatima, Mahesh Kumar Batra, Musa Karim","doi":"10.1007/s00059-025-05326-w","DOIUrl":"10.1007/s00059-025-05326-w","url":null,"abstract":"Background: In this study, we compared the incidence of short-term outcomes between two groups of patients based on the occurrence of intra-procedural slow-flow/no-reflow phenomenon (SF/NR) and identified predictors of short-term outcomes. This study enrolled a consecutive series of patients diagnosed with ST-elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI).Methods: The patients were divided into two groups based on the presence or absence of SF/NR, and the incidence of short-term major adverse cardiovascular events (MACE) was compared between the two groups. Furthermore, the study aimed to identify predictors of short-term mortality in these patients. A total of 2582 patients were included, of whom 79.1% (n=2042) were male.Results: The average age of the patients was 55.7 ± 11.2 years. Intra-procedural SF/NR was observed in 21.7% (560) of the patients. During median short-term follow-up of 180 days (144-205), patients with SF/NR exhibited a higher incidence of all-cause mortality (23.6% vs. 12.3%; p < 0.001) and MACE (30.4% vs. 16.9%; p < 0.001), with a hazard ratio of 1.82 (1.46-2.27; p < 0.001) and 1.69 (1.39-2.05; p < 0.001), respectively. Among patients with SF/NR, the following were found to be independent predictors of short-term mortality (adjusted odds ratios): total ischemic time, 1.04 (1.00-1.07; p = 0.041); random blood sugar levels, 1.01 (1.00-1.01; p < 0.001); intubation status, 2.79 (1.26-6.18; p = 0.011); post-procedural sub-optimal flow, 1.76 (1.04-2.98; p = 0.034); and intra-procedural arrhythmias, 5.48 (2.03-14.79; p < 0.001).Conclusion: The presence of intra-procedural SF/NR has significant prognostic implications. Patients with intra-procedural SF/NR face a significantly higher risk of short-term adverse outcomes.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"56-63"},"PeriodicalIF":0.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[ESC/EACTS guidelines 2025 on the treatment of valvular heart disease : New standards in diagnostics and treatment]. [ESC/EACTS 2025年瓣膜性心脏病治疗指南：诊断和治疗新标准]。

IF 0.9 4区医学

Herz Pub Date : 2026-02-01 Epub Date: 2025-11-12 DOI: 10.1007/s00059-025-05349-3

Anna Juliane Buch, Mateo Marin-Cuartas, Michael A Borger, Holger Thiele, Janine Pöss

{"title":"[ESC/EACTS guidelines 2025 on the treatment of valvular heart disease : New standards in diagnostics and treatment].","authors":"Anna Juliane Buch, Mateo Marin-Cuartas, Michael A Borger, Holger Thiele, Janine Pöss","doi":"10.1007/s00059-025-05349-3","DOIUrl":"10.1007/s00059-025-05349-3","url":null,"abstract":"The treatment of valvular heart disease plays an important role in cardiovascular medicine. The 2025 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) guidelines for the management of valvular heart disease set new standards for diagnostics and treatment based on scientific evidence with the aim to avoid both undertreatment and overtreatment. Recommendations for interventional treatment of valvular diseases are given greater importance compared to the 2021 guidelines. At the same time, surgical expertise remains indispensable, especially in younger patients and those with complex anatomy. Particular emphasis is placed on precise diagnostics using multimodal imaging, the recommendation for treatment of patients in high-volume centers (Heart Valve Centers) and an optimal patient selection by the multidisciplinary heart team. The ESC/EACTS guidelines advocate individualized, multidisciplinary treatment decisions based on the best available evidence. In practice, this can only be achieved by more intensive cooperation between the individual institutions of outpatient and inpatient care as well as specialized centers.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"26-36"},"PeriodicalIF":0.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145495311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[ESC Guidelines on cardiovascular diseases and pregnancy-most important facts of the 2025 update]. [ESC心血管疾病和妊娠指南- 2025年更新的最重要事实]。

IF 0.9 4区医学

Herz Pub Date : 2026-02-01 Epub Date: 2025-12-18 DOI: 10.1007/s00059-025-05358-2

Ute Seeland

{"title":"[ESC Guidelines on cardiovascular diseases and pregnancy-most important facts of the 2025 update].","authors":"Ute Seeland","doi":"10.1007/s00059-025-05358-2","DOIUrl":"10.1007/s00059-025-05358-2","url":null,"abstract":"The 2025 European Society of Cardiology (ESC) Guidelines on cardiovascular disease in pregnancy represents the second revision of the guideline versions published in 2011 and 2018. The new version aims to incorporate the most up-to-date evidence and update the resulting recommendations for clinical practice. The experts appointed by the ESC constitute a new task force compared with the first two versions. However, the thematic focus does not differ fundamentally from the 2018 guidelines. In view of the expanding evidence base, several chapters have become substantially more precise, for example those on risk stratification in women with pre-existing cardiovascular disease; the need for structured, obligatory postpartum follow-up in the event of complications during pregnancy; and the recommended measures for pre-pregnancy screening and counselling. The recommendations continue to be based predominantly on level C evidence, i.e., on expert opinion and consensus. Since the thalidomide scandal in 1962, there have been very few prospective randomized trials including pregnant women. Explicit presentation of level C evidence is therefore particularly important, as individual physicians are only rarely involved in the care of pregnant women. This task is demanding, because both the pregnant woman and the fetus require individual consideration. This should, however, not be discouraging but rather viewed as a positive challenge. This work is substantially supported by the establishment of the institution of a \"Pregnancy Heart Team.\" These teams, usually available 24/7 in larger centers, ensure interdisciplinary collaboration among multiple specialties and professions in order to arrive at the best possible decisions for both mother and child. The 2025 guidelines devote an expanded chapter to this topic.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"18-25"},"PeriodicalIF":0.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[2025 ESC Guidelines-new and revised recommendations]. [2025 ESC指南-新的和修订的建议]。

IF 0.9 4区医学

Herz Pub Date : 2026-02-01 Epub Date: 2026-01-29 DOI: 10.1007/s00059-025-05356-4

Rolf Dörr, Bernhard Maisch

引用次数: 0

[ESC guidelines on myocarditis and pericarditis : First combined European guidelines for myocarditis and pericarditis]. [ESC心肌炎和心包炎指南：首次合并欧洲心肌炎和心包炎指南]。

IF 0.9 4区医学

Herz Pub Date : 2026-02-01 Epub Date: 2026-01-09 DOI: 10.1007/s00059-025-05355-5

Bernhard Maisch, Jan Gröschel, Bettina Heidecker, Jeanette Schulz-Menger

{"title":"[ESC guidelines on myocarditis and pericarditis : First combined European guidelines for myocarditis and pericarditis].","authors":"Bernhard Maisch, Jan Gröschel, Bettina Heidecker, Jeanette Schulz-Menger","doi":"10.1007/s00059-025-05355-5","DOIUrl":"10.1007/s00059-025-05355-5","url":null,"abstract":"The new guidelines for myocarditis and pericarditis from the European Society of Cardiology (ESC) are the first guidelines for myocarditis and for the first time they also combine the two entities. A key aspect is the introduction of the term inflammatory myopericardial syndrome (IMPS), an umbrella term that covers the spectrum of both diseases and enables uniform diagnostics and treatment but in particular draws attention to the fact that there are overlapping causes, diagnostic approaches and treatment options. Other major aspects relate to noninvasive diagnostics using multimodal imaging. There is a paradigm shift that enables the definitive diagnosis of myocarditis also using cardiovascular magnetic resonance imaging. An etiologically oriented treatment mostly requires an endomyocardial biopsy in pericardial effusion cytological work-up is instrumental. Furthermore, an intuitive risk stratification is introduced, which influences both the treatment and follow-up examinations and involves abandoning fixed waiting periods with respect to resuming sports and work. Diagnostic algorithms are based on the initial symptoms, such as chest pain, heart failure and arrhythmia and integrate the risk stratification into the treatment process. For pericarditis, innovative treatment approaches using interleukin‑1 antagonists are coming to the fore. Another focus is the consideration of genetic factors, which are particularly relevant in recurrent forms.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"12-17"},"PeriodicalIF":0.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12855212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[ESC guidelines on dyslipidemia update 2025 : New recommendations for the practice]. [ESC关于血脂异常的指南更新2025：新的实践建议]。

IF 0.9 4区医学

Herz Pub Date : 2026-02-01 Epub Date: 2025-12-09 DOI: 10.1007/s00059-025-05354-6

Anna Hohneck, Oliver Weingärtner

{"title":"[ESC guidelines on dyslipidemia update 2025 : New recommendations for the practice].","authors":"Anna Hohneck, Oliver Weingärtner","doi":"10.1007/s00059-025-05354-6","DOIUrl":"10.1007/s00059-025-05354-6","url":null,"abstract":"The 2025 update of the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines on dyslipidemia introduce important innovations based on new evidence. The risk assessment is now conducted using the systematic coronary risk evaluation 2 (SCORE2) and SCORE2-OP (older persons), which enable improved stratification, particularly in older individuals. In addition, risk modifiers, such as family history, ethnicity, comorbidities and the biomarkers elevated highly sensitive C‑reactive protein (hs-CRP) or lipoprotein(a) (Lpa), have been introduced. Risk categories have been refined while low-density lipoprotein cholesterol (LDL-C) target values and the principle of stepwise treatment remain unchanged. A major focus is on the acute coronary syndrome: the immediate initiation of high-intensity statin treatment, mostly in combination with ezetimibe is recommended. Increasingly more important are elevated Lp(a) levels and special subgroups: in people with human immunodeficiency virus (HIV), statin treatment is recommended over the age of 40 years regardless of the LDL‑C as well as in high-risk patients undergoing anthracycline treatment. The use of dietary supplements and vitamins for prevention, however, are discouraged. The update reinforces the principle of risk-adapted LDL‑C target values, expands the treatment options and emphasizes the need for early, consistent lipid-lowering with practical recommendations.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"4-11"},"PeriodicalIF":0.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The 2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease : A successful plea for psychocardiology]. [2025年ESC关于心理健康和心血管疾病的临床共识声明：对心理心脏病学的成功呼吁]。

IF 0.9 4区医学

Herz Pub Date : 2026-02-01 Epub Date: 2026-01-04 DOI: 10.1007/s00059-025-05357-3

Malte Meesmann, Karl-Heinz Ladwig

{"title":"[The 2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease : A successful plea for psychocardiology].","authors":"Malte Meesmann, Karl-Heinz Ladwig","doi":"10.1007/s00059-025-05357-3","DOIUrl":"10.1007/s00059-025-05357-3","url":null,"abstract":"The negative impact of psychological factors on the development and course of cardiovascular disease is impressively documented in the European Society of Cardiology (ESC) 2025 Clinical Consensus Statement on mental health and cardiovascular disease (ESC-CCS-2025), which cites a total of 687 references. In particular, chronic stress, depression, anxiety disorders, and post-traumatic stress disorder can increase the cardiovascular risk by up to twofold, and these factors are often associated with an unhealthy lifestyle (smoking, unhealthy diet, physical inactivity, obesity). Conversely, due to their often existentially threatening nature, cardiovascular diseases can secondarily lead to significant psychological distress. Based on this broad body of evidence, readers are encouraged to apply this knowledge in clinical practice as directly and extensively as possible. As there are several barriers to implementing these recommendations, the ACTIVE principles propose guidance on how structures can be improved or newly created in order to enhance the diagnosis and treatment of psychological distress and mental disorders in patients with cardiovascular disease. To this end, establishment of a \"Psycho-Cardio team\" and expansion of a stepped-care model are recommended. The statement also emphasizes that caregiving relatives of patients may themselves experience severe emotional distress and often require support. Furthermore, the situation of patients with a primary, severe mental disorder is highlighted, as their cardiovascular care is frequently characterized by stigma and undertreatment. In our view, the ESC-CCS-2025 represents a milestone in psychocardiology, calling on all of us to translate this knowledge into practice and to create or expand effective structures of care.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":"37-44"},"PeriodicalIF":0.9,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic significance of H2FPEF and HFA-PEFF scores with oncostatin M levels in heart failure with preserved ejection fraction. H2FPEF和HFA-PEFF评分与抑素M水平对保留射血分数心衰的诊断意义。

IF 0.9 4区医学

Herz Pub Date : 2026-01-13 DOI: 10.1007/s00059-025-05362-6

Hasan Sari, Oznur Keskin, Yakup Alsancak

{"title":"Diagnostic significance of H2FPEF and HFA-PEFF scores with oncostatin M levels in heart failure with preserved ejection fraction.","authors":"Hasan Sari, Oznur Keskin, Yakup Alsancak","doi":"10.1007/s00059-025-05362-6","DOIUrl":"https://doi.org/10.1007/s00059-025-05362-6","url":null,"abstract":"Background: Heart failure with preserved ejection fraction (HFpEF) represents approximately half of all heart failure cases, and its prevalence is rising with an aging population and increasing comorbidities. Diagnosis is challenging due to heterogeneous clinical features and nonspecific symptoms. To improve diagnostic accuracy, scores such as the HFA-PEFF (Heart Failure Association Pre-test Assessment, Echocardiography & Natriuretic Peptide, Functional Testing, Final Etiology) and H2FPEF have been proposed. Oncostatin M (OSM), a cytokine of the interleukin‑6 family, is involved in cardiac inflammation, fibrosis, and remodeling, but its diagnostic role in HFpEF remains unclear.Methods: This single-center, cross-sectional study enrolled 71 patients with suspected HF symptoms (dyspnea, fatigue, edema) and a left ventricular ejection fraction ≥ 50%. Demographic, laboratory, and echocardiographic data were recorded. HFpEF likelihood was assessed using the HFA-PEFF and H2FPEF scores. Serum OSM levels were measured, and patients were classified into low-intermediate- and high-risk groups.Results: Mean patient age was 67.0 years (63.4% female). In the high-risk H2FPEF group, only hypertension showed a significant association (p = 0.032). By contrast, the high-risk HFA-PEFF group showed higher left atrial volume index, left ventricular mass index, and E/e' ratio; NT-proBNP and OSM levels were also significantly increased (51.3 vs. 14.4 pg/mL; p < 0.001). Receiver operating characteristic analysis showed that OSM had strong discriminatory power for the HFA-PEFF but not the H2FPEF score.Conclusion: Serum OSM levels correlated more strongly with the HFA-PEFF score, which incorporates structural and functional cardiac parameters. Thus, OSM may serve as a complementary biomarker to improve HFpEF diagnosis when used with the HFA-PEFF scoring system.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145958947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atherogenic index as an associative marker for coronary artery disease. 动脉粥样硬化指数作为冠状动脉疾病的相关标志物。

IF 0.9 4区医学

Herz Pub Date : 2026-01-09 DOI: 10.1007/s00059-025-05361-7

Basavaraj Utagi, Dilip Johny, Aditya Ojha, Adesh Kumar

{"title":"Atherogenic index as an associative marker for coronary artery disease.","authors":"Basavaraj Utagi, Dilip Johny, Aditya Ojha, Adesh Kumar","doi":"10.1007/s00059-025-05361-7","DOIUrl":"10.1007/s00059-025-05361-7","url":null,"abstract":"Background: Coronary artery disease (CAD) is a significant global health burden, warranting pragmatic, low-cost biomarkers for effective risk stratification. The atherogenic index of plasma (AIP), calculated as log(TG/HDL-C), is a lipid-derived indicator of cardiometabolic risk. We evaluated AIP as an associative marker for CAD and compared its diagnostic performance with commonly used biomarkers.Methods: In a hospital-based, angiography-confirmed case-control cohort (n = 340; 211 cases, 129 controls), we assessed AIP alongside uric acid, creatinine, neutrophil-to-lymphocyte ratio (NLR), TG/HDL‑C, HbA1c, and ejection fraction. Group characteristics were summarized using descriptive statistics, chi-square tests, and ANOVA. Associations with CAD were examined using multivariable logistic regression adjusted for age, sex, body mass index, diabetes, hypertension, smoking status, and statin use. Discriminative performance was evaluated via receiver operating characteristic (ROC) analysis, with pairwise comparisons conducted using DeLong's test.Results: Values of AIP (OR 1.42, 95% CI 1.18-1.69; p = 0.012), uric acid (OR 1.20, 95% CI 1.02-1.42; p = 0.032), and creatinine (OR 1.69, 95% CI 1.03-2.76; p = 0.038) were independently associated with CAD. HbA1c, TG/HDL‑C, NLR, and ejection fraction were not significantly associated in multivariable models. Values of AIP increased with greater angiographic severity. In ROC analysis, AIP showed superior discriminatory ability to uric acid, creatinine, NLR, and HbA1c (all p < 0.05, DeLong test), and performed comparably to TG/HDL‑C, consistent with AIP being its log transformation.Conclusion: Readily available AIP offers incremental prognostic value in symptomatic patients with suspected CAD. These findings are hypothesis-generating; thus, thresholds should be interpreted cautiously pending prospective, multicenter studies.","PeriodicalId":12863,"journal":{"name":"Herz","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Herz最新文献